AUTHORS
Nikoloz Papiashvili, MD, Ayodeji David Johnson, MD2, Anano Nebieridze, MD3, Tornike Zabakhidze, MD4
AFFILIATIONS
1 Boston Medical Center - Brighton, Boston, Massachusetts, United States
2 Boston Medical Center - Brighton, Boston, Massachusetts, United States
3 Boston Medical Center - Brighton, Boston, Massachusetts, United States
4 Boston Medical Center - Brighton, Boston, Massachusetts, United States
ABSTRACT
Background
Anticoagulation in patients with atrial fibrillation and concomitant hematologic malignancy represents a particularly difficult clinical scenario, as these patients often face competing risks for thrombosis and bleeding. Data directly comparing individual direct oral anticoagulants in this population are limited. We evaluated outcomes among patients with hematologic malignancies and atrial fibrillation treated with apixaban or rivaroxaban, comparing rates of major bleeding, thrombotic events, and all-cause mortality using a large de-identified database.
Methods
A retrospective cohort study was conducted using the TriNetX Research Network. We identified patients aged ≥ 18 years with both atrial fibrillation and hematologic malignancy prior to anticoagulant initiation. Hematologic malignancies included myeloid neoplasms (eg, myeloid leukemias, myelodysplastic syndromes) and lymphoid neoplasms (eg, lymphoid leukemias, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma). Cohorts were defined based on initial treatment with apixaban or rivaroxaban. A 12-month washout period was applied and patients receiving other anticoagulants were excluded. Propensity score matching was performed (1:1) to balance demographics, comorbidities, prior bleeding or thrombotic events, and malignancy type. Outcomes included major bleeding, thrombotic events, and all-cause mortality, which were assessed over a 3-year follow-up period.
Results
After matching, each cohort included 3,596 patients with well-balanced baseline characteristics. At 3 years, the cumulative incidence of major bleeding was 14.3% with apixaban compared to 17.9% with rivaroxaban, corresponding to a lower hazard of major bleeding (HR 0.861, 95% CI 0.767-0.967). The cumulative incidence of thrombotic complications was also lower with apixaban (9.9% vs. 13.0%), with a lower hazard of thrombotic complications (HR 0.820, 95% CI 0.714-0.941). No significant difference in all-cause mortality was observed between cohorts.
Among patients with lymphoid malignancies, apixaban was associated with a lower hazard of major bleeding (HR 0.839, 95% CI 0.736-0.957) and thrombotic complications (HR 0.811, 95% CI 0.694-0.949). However, apixaban was also associated with a higher hazard of all-cause mortality in this subgroup (HR 1.157, 95% CI 1.022-1.309). These associations were not observed among patients with myeloid malignancies. Similarly, no significant differences in outcomes were observed among patients with platelet counts < 100 × 10³/µL.
Conclusions
Among patients with hematologic malignancies and atrial fibrillation, apixaban was associated with lower rates of major bleeding and thrombotic complications compared with rivaroxaban, with no significant difference in all-cause mortality. These findings suggest that apixaban may be associated with more favorable safety and effectiveness outcomes in this population. However, the observed increase in mortality among patients with lymphoid malignancies warrants further investigation. Prospective studies are needed to validate these findings and further inform anticoagulant selection in patients with hematologic malignancies.
DISCLOSURES
Nikoloz Papiashvili, MD: No relevant conflicts of interest to declare.